INAB
What one share of In8bio holds
Biological Products, (No Diagnostic Substances)
We are a leading clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers ("TCEs") for cancer and autoimmune diseases.
In8bio’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$1.48 |
|---|---|
| Cash and investments | $1.84 |
| Book value | $1.86 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$90.73 | — | −$62.59 | — | −$132.12 |
| 2021 | — | −$44.09 | — | −$40.65 | — | −$60.99 |
| 2022 | — | −$40.81 | — | −$34.51 | — | $27.78 |
| 2023 | — | −$30.14 | — | −$23.45 | — | $17.28 |
| 2024 | — | −$17.05 | — | −$13.53 | — | $5.99 |
| 2025 | — | −$4.44 | — | −$2.91 | — | $2.82 |